Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you consider a stock's sales trends when choosing among companies? Since most firms rely on sales as their primary source of profits, a sales analysis should be high on the priority list.

We ran a screen with this idea in mind, beginning with stocks of the healthcare sector. We screened the sector for high-growth names, with 5-year projected EPS growth above 20%.

We then screened these names for those with strong sales trends relative to inventory, with faster growth in revenue than inventory year-over-year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered a good sign.

To screen for healthy liquidity, we also only focused on those companies with inventory declining as a percent of current assets.

Interactive Chart: Press Play to compare changes in market cap over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these stocks will meet their high growth expectations? Use this list as a starting point for your own analysis.

List sorted by difference between growth in revenue and inventory over the past year

1. Anika Therapeutics Inc. (NASDAQ:ANIK): Develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Market cap at $211.2M, most recent closing price at $15.74. 5-year projected EPS growth at 30.00%. Revenue grew by 25.27% during the most recent quarter ($18.44M vs. $14.72M y/y). Inventory grew by -18.44% during the same time period ($7.3M vs. $8.95M y/y). Inventory, as a percentage of current assets, decreased from 15.89% to 11.38% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

2. Quidel Corp. (NASDAQ:QDEL): Engages in the development, manufacture, and marketing of diagnostic testing solutions for applications primarily in infectious diseases, and reproductive and women's health. Market cap at $584.37M, most recent closing price at $17.94. 5-year projected EPS growth at 17.50%. Revenue grew by 21.07% during the most recent quarter ($38.39M vs. $31.71M y/y). Inventory grew by -17.28% during the same time period ($14.65M vs. $17.71M y/y). Inventory, as a percentage of current assets, decreased from 31.61% to 13.99% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

3. ZOLL Medical Corp. (NASDAQ:ZOLL): Develops, manufactures, and markets resuscitation devices and related software solutions worldwide. Market cap at $2.07B, most recent closing price at $93.0. 5-year projected EPS growth at 36.67%. Revenue grew by 18.2% during the most recent quarter ($133.75M vs. $113.16M y/y). Inventory grew by -19.84% during the same time period ($56.67M vs. $70.7M y/y). Inventory, as a percentage of current assets, decreased from 26.89% to 21.57% during the most recent quarter (comparing 13 weeks ending 2012-01-01 to 13 weeks ending 2011-01-02).

4. ResMed Inc. (NYSE:RMD): Engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Market cap at $4.51B, most recent closing price at $31.59. 5-year projected EPS growth at 18.10%. Revenue grew by 8.74% during the most recent quarter ($332.74M vs. $305.99M y/y). Inventory grew by -14.18% during the same time period ($184.42M vs. $214.89M y/y). Inventory, as a percentage of current assets, decreased from 18.76% to 14.79% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

5. Cyberonics Inc. (NASDAQ:CYBX): Engages in the design, development, manufacture, sale, and marketing of implantable medical devices that provide vagus nerve stimulation therapy for the treatment of refractory epilepsy and treatment-resistant depression. Market cap at $1.01B, most recent closing price at $37.14. 5-year projected EPS growth at 26.25%. Revenue grew by 15.85% during the most recent quarter ($54.54M vs. $47.08M y/y). Inventory grew by -11.32% during the same time period ($13.95M vs. $15.73M y/y). Inventory, as a percentage of current assets, decreased from 10.98% to 10.33% during the most recent quarter (comparing 13 weeks ending 2012-01-27 to 13 weeks ending 2011-01-28).

6. Alphatec Holdings, Inc. (NASDAQ:ATEC): Engages in the design, development, manufacture, and marketing of products for the surgical treatment of spine disorders, primarily focused on the aging spine. Market cap at $205.16M, most recent closing price at $2.29. 5-year projected EPS growth at 67.00%. Revenue grew by 7.58% during the most recent quarter ($49.51M vs. $46.02M y/y). Inventory grew by -11.06% during the same time period ($45.92M vs. $51.63M y/y). Inventory, as a percentage of current assets, decreased from 42.04% to 39.44% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

7. STAAR Surgical Company (NASDAQ:STAA): Designs, develops, manufactures, and sells implantable lenses for the cataracts and refractive surgery. Market cap at $393.6M, most recent closing price at $11.11. 5-year projected EPS growth at 50.00%. Revenue grew by 13.83% during the most recent quarter ($16.38M vs. $14.39M y/y). Inventory grew by 3.7% during the same time period ($10.93M vs. $10.54M y/y). Inventory, as a percentage of current assets, decreased from 35.15% to 28.28% during the most recent quarter (comparing 3 months ending 2011-12-30 to 3 months ending 2010-12-31).

8. Novo Nordisk A/S (NYSE:NVO): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. Market cap at $101.12B, most recent closing price at $148.54. 5-year projected EPS growth at 15.63%. Revenue grew by 12.38% during the most recent quarter ($18,120M vs. $16,124M y/y). Inventory grew by -2.64% during the same time period ($9,433M vs. $9,689M y/y). Inventory, as a percentage of current assets, decreased from 25.98% to 23.83% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

9. Natus Medical Inc. (NASDAQ:BABY): Develops, manufactures, and markets neurodiagnostic and newborn care products worldwide. Market cap at $324.72M, most recent closing price at $11.48. 5-year projected EPS growth at 18.50%. Revenue grew by 1.49% during the most recent quarter ($64.11M vs. $63.17M y/y). Inventory grew by -11.27% during the same time period ($33.39M vs. $37.63M y/y). Inventory, as a percentage of current assets, decreased from 29.18% to 25.44% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

10. Tornier N.V. (NASDAQ:TRNX): Operates as a medical device company that designs, manufactures, and markets devices for joint replacement and soft tissue repair that enable surgical specialists to improve patients' lives by restoring motion and physical vitality. Market cap at $912.78M, most recent closing price at $23.73. 5-year projected EPS growth at 20.00%. Revenue grew by 12.68% during the most recent quarter ($69.04M vs. $61.27M y/y). Inventory grew by 3.03% during the same time period ($79.88M vs. $77.53M y/y). Inventory, as a percentage of current assets, decreased from 44.76% to 40.17% during the most recent quarter (comparing 13 weeks ending 2012-01-01 to 13 weeks ending 2011-01-02).

11. Masimo Corporation (NASDAQ:MASI): Develops, manufactures, and markets noninvasive patient monitoring products worldwide. Market cap at $1.27B, most recent closing price at $22.39. 5-year projected EPS growth at 17.67%. Revenue grew by 6.41% during the most recent quarter ($112.34M vs. $105.57M y/y). Inventory grew by 2.02% during the same time period ($45.94M vs. $45.03M y/y). Inventory, as a percentage of current assets, decreased from 20.69% to 17.47% during the most recent quarter (comparing 13 weeks ending 2011-12-31 to 13 weeks ending 2011-01-01).

12. Trinity Biotech plc (NASDAQ:TRIB): Develops, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. Market cap at $244.23M, most recent closing price at $11.32. 5-year projected EPS growth at 16.00%. Revenue grew by 7.4% during the most recent quarter ($20.03M vs. $18.65M y/y). Inventory grew by 3.54% during the same time period ($19.3M vs. $18.64M y/y). Inventory, as a percentage of current assets, decreased from 18.16% to 17.43% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 12 High-Growth Healthcare Stocks With Strong Inventory Trends